Global Diabetic Gastroparesis Treatment Market Growth (Status and Outlook) 2025-2031

The global Diabetic Gastroparesis Treatment market size is predicted to grow from US$ 3725 million in 2025 to US$ 5320 million in 2031; it is expected to grow at a CAGR of 6.1% from 2025 to 2031.

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.



During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.



Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Market is not concentrated. Sumitomo, Johnson & Johnson, Sanofi are the leaders of the industry, and hold the key technologies and patent, with high-end customers. Top 3 manufacturer accounted for 7.4% market share in 2019.

LPI (LP Information)' newest research report, the “Diabetic Gastroparesis Treatment Industry Forecast” looks at past sales and reviews total world Diabetic Gastroparesis Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Diabetic Gastroparesis Treatment sales for 2025 through 2031. With Diabetic Gastroparesis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Gastroparesis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Diabetic Gastroparesis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Diabetic Gastroparesis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Gastroparesis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Gastroparesis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Gastroparesis Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Gastroparesis Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Drugs
Surgical Treatment Products

Segmentation by Application:
Hospital Pharmacies
Private Clinics
Drug Stores
E-Commerce

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sumitomo
Johnson & Johnson
Sanofi
Medtronic
Pfizer
Teva
Boston Scientific

Please note: The report will take approximately 2 business days to prepare and deliver.